Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharma MarPHMMF 79 3-1 Month Momentum % is -25.35% as of Jul. 31, 2026. GuruFocus rates PHMMF with a GF Score™ of 79/100 and a GF Value™ of $91.34 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,389 Biotechnology companies, Pharma Mar ranks worse than 71.2% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-31), Pharma Mar's 3-1 Month Momentum % is -25.35%.
The industry rank for Pharma Mar's 3-1 Month Momentum % or its related term are showing as below:
PHMMF's 3-1 Month Momentum % is ranked worse than 71.2% of 1389
companies
in the Biotechnology industry
Industry Median: -7.65
vs PHMMF: -25.35
Pharma Mar (OTCPK:PHMMF) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Pharma Mar 3-1 Month Momentum % Related Terms
PHMMF vs VRTX, REGN, RVMD: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Pharma Mar's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma Mar 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharma Mar's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Pharma Mar's 3-1 Month Momentum % falls into.
Pharma Mar (OTCPK:PHMMF) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma Mar (PHMMF) has a 3-1 Month Momentum % of -25.35% as of Jul. 31, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Pharma Mar and its competitors. According to the industry distribution chart, Pharma Mar ranks #989 out of 1389 companies in the Biotechnology industry, placing it in the top 71.2%.
Is Pharma Mar's 3-1 Month Momentum % too high?
Pharma Mar's current 3-1 Month Momentum % is -25.35%. Based on the distribution chart, Pharma Mar ranks #989 out of 1389 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Pharma Mar has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharma Mar's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharma Mar ranks #989 out of 1389 companies for 3-1 Month Momentum %. This places Pharma Mar in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Pharma Mar and its competitors. Pharma Mar's current 3-1 Month Momentum % is -25.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Mar stock overvalued right now?
Based on GuruFocus' analysis, Pharma Mar (PHMMF) is currently considered Fairly Valued. The stock's GF Value™ is $91.34, compared to a current price of $86.09 — trading 5.8% below its estimated fair value. The current 3-1 Month Momentum % is -25.35%. Pharma Mar's overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Pharma Mar (PHMMF), the current 3-1 Month Momentum % is -25.35% as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma Mar (PHMMF) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma Mar stock appears to be undervalued.
The current stock price of $86.09 is trading 5.8% below its estimated GF Value™ of $91.34.
GuruFocus considers Pharma Mar to be Fairly Valued.
Key valuation signals for PHMMF:
3-1 Month Momentum %: -25.35%
GF Value™: $91.34 vs. price of $86.09 (5.8% below fair value)
No single metric tells the full story. See the PHMMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
79GF Score
Get the complete analysis for PHMMF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHMMF has been successfully added to your 
